JP2009522578A5 - - Google Patents

Download PDF

Info

Publication number
JP2009522578A5
JP2009522578A5 JP2008549563A JP2008549563A JP2009522578A5 JP 2009522578 A5 JP2009522578 A5 JP 2009522578A5 JP 2008549563 A JP2008549563 A JP 2008549563A JP 2008549563 A JP2008549563 A JP 2008549563A JP 2009522578 A5 JP2009522578 A5 JP 2009522578A5
Authority
JP
Japan
Prior art keywords
patient
marker
determining
markers
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008549563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522578A (ja
JP5221381B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/000216 external-priority patent/WO2007081768A2/en
Publication of JP2009522578A publication Critical patent/JP2009522578A/ja
Publication of JP2009522578A5 publication Critical patent/JP2009522578A5/ja
Application granted granted Critical
Publication of JP5221381B2 publication Critical patent/JP5221381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008549563A 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用 Active JP5221381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75613106P 2006-01-04 2006-01-04
US60/756,131 2006-01-04
PCT/US2007/000216 WO2007081768A2 (en) 2006-01-04 2007-01-04 Use of he4 and other biochemical markers for assessment of ovarian cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012226640A Division JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Publications (3)

Publication Number Publication Date
JP2009522578A JP2009522578A (ja) 2009-06-11
JP2009522578A5 true JP2009522578A5 (enExample) 2010-02-25
JP5221381B2 JP5221381B2 (ja) 2013-06-26

Family

ID=38256906

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
JP2008549563A Active JP5221381B2 (ja) 2006-01-04 2007-01-04 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008549562A Active JP5164855B2 (ja) 2006-01-04 2007-01-04 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012226640A Active JP5711196B2 (ja) 2006-01-04 2012-10-12 卵巣癌を判定するためのｈｅ４及び他の生化学マーカーの使用

Country Status (7)

Country Link
US (8) US20070286865A1 (enExample)
EP (6) EP2423321A3 (enExample)
JP (3) JP5164855B2 (enExample)
CN (3) CN101473041B (enExample)
ES (2) ES2650244T3 (enExample)
PL (1) PL2982761T3 (enExample)
WO (2) WO2007081767A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214748A2 (en) * 1999-06-09 2002-06-19 Moltech Corporation Methods of preparing electrochemical cells
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
WO2006119155A2 (en) * 2005-05-02 2006-11-09 The Brigham And Women's Hospital, Inc. Diagnostic serum antibody profiling
CN101473041B (zh) * 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用
MX2008009592A (es) * 2006-01-27 2008-09-08 Tripath Imaging Inc Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
EP2087152B1 (en) 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
AU2008226587A1 (en) * 2007-03-09 2008-09-18 Tripath Imaging, Inc. HE4 monoclonal antibodies and methods for their use
JP5144742B2 (ja) * 2007-03-29 2013-02-13 フジレビオ ダイアグノスティックス インコーポレイテッド 乳がんの評価のためのｈｅ４の使用
CN101377502A (zh) * 2007-08-31 2009-03-04 北京科美东雅生物技术有限公司 肿瘤相关抗原72-4化学发光免疫分析测定试剂盒及其制备方法
US8642347B2 (en) * 2008-01-31 2014-02-04 The Brigham And Women's Hospital, Inc. Urinary CA125 peptides as biomarkers of ovarian cancer
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
RU2600891C2 (ru) * 2010-08-26 2016-10-27 Юниверсити Оф Вашингтон Тру Итс Сентер Фор Коммерсиализейшен Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
JP5887364B2 (ja) 2011-02-17 2016-03-16 フジレビオ ダイアグノスティックス インコーポレイテッド ＨＥ４ａの測定のための組成物および使用方法
GB2503148A (en) * 2011-02-24 2013-12-18 Vermillion Inc Biomarker panels diagnostic methods and test kits for ovarian cancer
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012170513A2 (en) * 2011-06-06 2012-12-13 Women & Infants' Hospital Of Rhode Island He4 based therapy for malignant disease
DE102012205164B4 (de) 2012-03-29 2021-09-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Projektionsdisplay und Verfahren zur Projektion virtueller Bilder
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
CN102890083B (zh) * 2012-09-28 2016-08-10 辽宁科骏生物有限公司 化学发光底物溶液和含其的试剂盒及应用其的检测方法
CN104655858B (zh) * 2015-03-12 2016-02-10 德迈基生物技术（北京）有限公司 定量检测人附睾分泌蛋白-4的荧光免疫层析试剂盒及其制备方法
WO2016154629A1 (en) 2015-03-26 2016-09-29 Woman & Infants' Hospital Of Rhode Island Therapy for malignant disease
RU2585959C1 (ru) * 2015-06-22 2016-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ дифференциальной диагностики асцитно-инфильтративной формы рака яичников и абдоминального туберкулёза
US10267802B2 (en) 2015-09-23 2019-04-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of prognosis and diagnosis of ovarian cancer
RU2624508C1 (ru) * 2016-06-29 2017-07-04 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования длительности ремиссии у больных раком вульвы
CN109690315A (zh) * 2016-07-08 2019-04-26 豪夫迈·罗氏有限公司 人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
EP4139289A1 (en) 2020-04-21 2023-03-01 University of Rochester Inhibitors of human epididymus protein 4
CN111781364B (zh) * 2020-08-25 2023-07-21 北京信诺卫康科技有限公司 Wnt7a和HE4联合用作早期卵巢癌生物标志物以及试剂盒
CA3202255A1 (en) 2020-12-21 2022-06-30 Hayley WARSINSKE Markers for the early detection of colon cell proliferative disorders
US20240385195A1 (en) * 2022-04-08 2024-11-21 Ajou University Industry-Academic Cooperation Foundation Peptide for detecting ca125 and use thereof
WO2023195629A1 (ko) * 2022-04-08 2023-10-12 아주대학교산학협력단 He4 검출용 펩타이드 및 그 용도
CN120254284B (zh) * 2025-06-03 2025-08-22 杭州广科安德生物科技有限公司 一种用于预测子宫内膜癌复发或转移风险的生物标志物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6998106B1 (en) * 1998-12-01 2006-02-14 Duke University Radioconjugation of internalizing antibodies
ATE328280T1 (de) 1999-02-26 2006-06-15 Pacific Northwest Res Inst Verfahren und zusammensetzungen zur karzinomdiagnose
US6770445B1 (en) 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
NZ562192A (en) * 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
WO2004018623A2 (en) * 2002-08-16 2004-03-04 Clinical Microarrays, Inc. Substrates for isolating, reacting and microscopically analyzing materials
AU2003290773A1 (en) * 2003-02-05 2004-09-06 Ciphergen Biosystems, Inc. Non-invasive assessment of intra-amniotic environment
DK1633784T3 (da) * 2003-05-09 2011-10-24 Diadexus Inc OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
CN1266475C (zh) * 2003-06-05 2006-07-26 马旭 一种用于诊断早期卵巢癌的四粘蛋白酶联免疫检测试剂盒
EP2026071B1 (en) * 2004-02-19 2013-07-31 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
US8486648B2 (en) * 2005-02-16 2013-07-16 Dana-Farber Cancer Institute, Inc. Methods of detecting ovarian cancer
AU2006262182B2 (en) * 2005-06-22 2012-04-05 Aspira Women’s Health Inc. Biomarker for ovarian cancer: CTAP3-related proteins
US8465929B2 (en) * 2005-06-24 2013-06-18 Vermillion, Inc. Biomarkers for ovarian cancer
CN101473041B (zh) 2006-01-04 2017-11-14 富士瑞必欧美国公司 He4与其它生化标记物在评估子宫内膜癌和子宫癌中的应用

Similar Documents

Publication Publication Date Title
JP2009522578A5 (enExample)
Jia et al. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis
Abel et al. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment
Oh et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma
WO2010065968A1 (en) Cancer detection markers
US11402381B2 (en) Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses
US10139412B2 (en) Semaphorin 3A as a diagnostic marker for urothelial cancer
CN102298053B (zh) 原发性肝细胞肝癌术后复发风险评估的组合抗体试剂盒
Park et al. Clinical significance of lymph node micrometastasis in stage I and II colon cancer
CN109425739A (zh) 一组蛋白作为肿瘤标志物在制备恶性肿瘤诊断试剂和试剂盒中的用途
CN107561280A (zh) 一种预测乳腺癌复发的试剂盒
Yu et al. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas
Provenzano et al. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple‐negative tumours
Tanaka et al. Prognostic significance of circulating tumor cells in patients with advanced esophageal cancer
Chen et al. Survivin as a useful adjunct marker for the grading of papillary urothelial carcinoma
Hashmi et al. Clinicopathologic patterns of adult renal tumors in Pakistan
CN109735619A (zh) 与非小细胞肺癌预后相关的分子标志物及其应用
US20180292410A1 (en) Methods of detecting a relapse of a lung adenocarcinoma based on marker human epididymis protein 4 (he4) and related uses
Yokoi et al. Immunophenotypic profile as a predictor of prognosis in advanced ovarian carcinoma
Alrashidy et al. Immunohistochemical differentiation between urothelial papillomas and papillary neoplasms of low malignant potential of the urinary bladder
CN116593702B (zh) 一种肺癌的生物标志物以及诊断系统
Makkai-Popa et al. Corelation of lymphocytic infiltrates with the prognosis of recurrent colo-rectal cancer
Cherciu et al. Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study
Wu et al. Correlation Between Drug Sensitivity Profiles of Ex Vivo Expanded Circulating Tumor Cells and Clinical Treatment Response in Pancreatic Ductal Adenocarcinoma Patients
JP3954605B2 (ja) 癌の遠隔転移の予後検査方法